After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease
Xconomy
FEBRUARY 28, 2019
Headed by former Amylin CEO Dan Bradbury, Equillium (NASDAQ: EQ ) has licensed the drug, itolizumab, which it calls EQ001, from Indian pharma giant Biocon Limited for development in the United States and Canada. Equillium was formed to advance.
Let's personalize your content